Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 4:43 p.m.

    📋 ImmunoGen, Inc. (IMGN) - Financial Results

    Filing Date: 2022-07-29

    Accepted: 2022-07-29 06:41:12

    Event Type: Financial Results

    Event Details:

    ImmunoGen Inc (was acquired by AbbVie (NYSE: ABBV) on 12/02/2024) (IMGN) Reports Q3 2022 Financial Results ImmunoGen Inc (was acquired by AbbVie (NYSE: ABBV) on 12/02/2024) (IMGN) announced its financial results for the period ending Q3 2022. Key Financial Highlights:
    • Revenue: 14162
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 373874
      • anticipated interactions with regulatory authorities, including that the FDA may determine that our BLA for mirvetuximab does not meet the conditions for accelerated approval; risks and uncertainties associated with the scale and duration of the COVID-19 pandemic and the resulting impact on ImmunoGen’s industry and business; and other factors as set forth in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 28, 2022

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Other Assets 48.42K 48.42K $0.00 +0.00%
    Other Long Term Liabilities 41.78K 41.78K $0.00 +0.00%
    Expenses Selling General Administrative 9.73K 40.44K $-30.71K -75.95%
    Loss From Operations -27.37K -83.91K $56.54K +67.38%
    Net Loss -30.74K -86.17K $55.42K +64.32%
    Other Assets 48.42K 48.42K $0.00 +0.00%
    Revenue 15.64K 15.64K $0.00 +0.00%
    Selling, General & Administrative 9.73K 40.44K $-30.71K -75.95%
    Loss from Operations -27.37K -83.91K $56.54K +67.38%
    Interest Expense -3.56K -2.33K $-1.23K -52.86%
    Net Loss -30.74K -86.17K $55.42K +64.32%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ImmunoGen Inc (was acquired by AbbVie (NYSE: ABBV) on 12/02/2024)
    • CIK: 0000855654
    • Ticker Symbol: IMGN
    • Period End Date: 2022-07-29
    • Document Type: 8-K

Search

News categories